Heron Therapeutics Inc. (NASDAQ:HRTX) shares traded up 2.8% on Tuesday . The company traded as high as $19.95 and last traded at $19.27, with a volume of 327,965 shares trading hands. The stock had previously closed at $18.74.

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald reissued a “buy” rating on shares of Heron Therapeutics in a report on Tuesday. Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Jefferies Group restated a “buy” rating and issued a $46.00 target price on shares of Heron Therapeutics in a research note on Wednesday, July 27th. Cowen and Company restated a “buy” rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. Finally, Leerink Swann restated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, June 27th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $50.30.

The stock has a 50-day moving average price of $17.70 and a 200 day moving average price of $18.85.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21. On average, equities research analysts expect that Heron Therapeutics Inc. will post ($3.82) earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the company. Bank of Montreal Can purchased a new stake in Heron Therapeutics during the fourth quarter worth approximately $3,010,000. California Public Employees Retirement System boosted its stake in Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock worth $2,419,000 after buying an additional 81,200 shares during the period. California State Teachers Retirement System boosted its stake in Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock worth $1,447,000 after buying an additional 1,000 shares during the period. Russell Frank Co boosted its stake in Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock worth $1,369,000 after buying an additional 15,585 shares during the period. Finally, GAM Holding AG boosted its stake in Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock worth $1,119,000 after buying an additional 9,400 shares during the period.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.